Abstract 1864P
Background
Globally, more than 1.3 mio adolescents and young adults (AYAs) are diagnosed with cancer each year. Long-term survival has increased due to improved cancer therapy; however, a potential side effect is reduced fertility. Despite development in fertility preservation uncertainty regarding future fertility is still of major concern to the AYAs. The aim of this study was to identify to what extent nulliparous, female AYAs with cancer have children after cancer treatment compared to nulliparous female AYAs without cancer.
Methods
This is a national register study based on the Danish National Assisted Reproductive Technology-Couple cohort including female AYAs diagnosed with cancer when aged 18-39 from 1978–2016. According to diagnosis onset, the female AYAs with cancer were randomly age-matched with 60 female AYAs without cancer (comparison group: CG). Study participants were followed until end of study, death, or migration (31/12-2017). Death was incorporated as a competing risk in all analyses. Hazard Ratio (HR) were calculated, comparing the female AYAs with cancer with the CG. HR was adjusted for time of diagnosis, immigration status, marital status, and educational level.
Results
33.3% of AYAs with cancer had at least one child after cancer treatment vs. 40% in the CG. Female AYAs with malignant melanoma had solely a higher HR of having children after cancer treatment compared to the CG. Female AYAs with leukaemia, breast and CNS cancer had the lowest HR of having children after cancer treatment, especially in the age interval 32-39 years. Table: 1864P
N (%) | ≥ 1 child after cancer N (%) | Adjusted HR (95% CI)* | |||
18-25 y | 26-31 y | 32-39 y | |||
All | 7519 (100) | 2505 (33.3) | 0.77 (0.72-0.82) | 0.65 (0.61-0.69) | 0.59 (0.52-0.67) |
Gyn cancer | 1773 (23.6) | 435 (24.5) | 0.49 (0.42-0.58) | 0.44 (0.38-0.50) | 0.39 (0.29-0.52) |
Breast cancer | 1115 (14.8) | 179 (16.1) | 0.63 (0.42-0.95) | 0.46 (0.37-0.56) | 0.35 (0.26-0.48) |
Mal melanoma | 1960 (26.1) | 1071 (54.6) | 1.02 (0.93-1.12) | 1.03 (0.93-1.13) | 1.13 (0.92-1.39) |
CNS cancer | 303 (4.0) | 65 (21.5) | 0.70 (0.51-0.97) | 0.40 (0.26-0.61) | 0.25 (0.06-0.97) |
Leukaemia | 258 (3.4) | 37 (14.3) | 0.39 (0.26-0.57) | 0.25 (0.09-0.65) | 0.41 (0.13-1.26) |
Lymphoma | 278 (3.7) | 78 (28.1) | 0.63 (0.47-0.85) | 0.48 (0.30-0.75) | 0.76 (0.32-1.84) |
CG | 499,616 | 199,861 (40.0) | 1 | 1 | 1 |
*Adjusted analysis is based on complete case sample, N=6275. Approximately 16% (6275/7519) is excluded in the adjusted analysis due to missing data.
Conclusions
A third of nulliparous, female AYAs with cancer had at least one child after cancer which is lower than for female AYAs without cancer. The HR for having children after cancer decrease with increased age being lowest in female AYAs with leukaemia, breast- and CNS cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2008P - Brazilian real-world data of immunotherapy (IO) in extensive disease small cell lung cancer (ES-SCLC)
Presenter: Flávia Duarte
Session: Poster session 05
2009P - CNS efficacy of immune checkpoint inhibitors when combined to stereotactic radiosurgery in extensive stage small cell lung cancer
Presenter: Muhammad Awidi
Session: Poster session 05
2010P - Non-invasive radiomics signature predicts response to combination chemoimmunotherapy in extensive-stage small cell lung cancer (ES SCLC)
Presenter: Stuthi Perimbeti
Session: Poster session 05
2011P - Machine-derived features of tumor infiltrating lymphocytes (TILs) as biomarkers of clinical outcomes to platinum chemotherapy in small cell lung cancer (SCLC)
Presenter: Prantesh Jain
Session: Poster session 05
2012P - Spatially resolved transcriptomics deciphers inter- and intra-tumor heterogeneity of small cell lung cancer
Presenter: xujie Sun
Session: Poster session 05
2013P - Investigating the clinical relevance of immune checkpoint expression in the peripheral blood of patients with small cell lung cancer (SCLC)
Presenter: Dimitrios Mavroudis
Session: Poster session 05
2014P - ATR inhibition upregulates PD-L1 and potentiates the antitumor immune response to chemoimmunotherapy in small cell lung cancer
Presenter: Triparna Sen
Session: Poster session 05
2015P - Association between gene characteristics and mutation abundance with the prognosis of small cell lung cancer
Presenter: Lian Yu
Session: Poster session 05
2016P - The role of galectin-1 in SCLC: Prognostic significance and therapeutic implications
Presenter: Arancha Cebrian
Session: Poster session 05
2017P - Comprehensive molecular profiling of small cell lung cancer patients treated with chemo-immunotherapy or chemotherapy alone
Presenter: Milena Urbini
Session: Poster session 05